Cravath’s London Office Moves to 100 Cheapside
On December 15, 2023, Cravath’s antitrust practice was ranked among the “Elite” in Global Competition Review’s 2024 edition of GCR 100, a guide to the world’s leading competition law and economics practices. This is the twelfth consecutive year the Firm has been ranked in the highest tier among New York Firms by GCR. The publication highlighted Cravath’s “bountiful antitrust work,” including its role in securing major victories for clients Louis Dreyfus Company in the denial of the DOJ’s request for an injunction to block its sale of Imperial Sugar Company; Illumina in a groundbreaking trial win rejecting the FTC’s challenge to its $8 billion acquisition of GRAIL; and Amgen in a successful defense against a “rare” FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics.
Related Practices & Industries
Related News & Insights
Deals & Cases
July 14, 2023
Louis Dreyfus Company and Imperial Sugar Company Win Appellate Victory Over DOJ
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
September 02, 2022
Illumina Secures Unprecedented Antitrust Trial Win in FTC’s Challenge to GRAIL Acquisition
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Deals & Cases
September 11, 2023
Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.